Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to examine if an experimental drug combination impacts the
survival rate of individuals with Leptomeningeal Metastases
This research study involves an experimental drug combination.
The names of the study drugs involved in this study are:
- Pembrolizumab
- Lenvatinib